Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is a Schedule IV controlled substance.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses may include other seizure disorders and anxiety.
## Adult Dosing
* **LGS:** The recommended starting dose is 5 mg twice daily.
* Titrate by 5-10 mg per day every week.
* **Usual Maintenance Dose:** 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day). Doses higher than 20 mg/day have not been shown to be more effective and may increase the risk of adverse effects.
## Pediatric Dosing
* **LGS (2 to less than 10 years of age):**
* Starting dose: 5 mg twice daily.
* Titrate by 2.5 mg to 5 mg per day every week.
* Usual maintenance dose: 5 mg to 10 mg twice daily.
* Maximum dose: 10 mg twice daily (20 mg/day).
* **LGS (10 to less than 30 kg):**
* Starting dose: 5 mg twice daily.
* Titrate by 5 mg per day every week.
* Usual maintenance dose: 10 mg twice daily.
* Maximum dose: 10 mg twice daily (20 mg/day).
* **LGS (30 kg and greater):**
* Starting dose: 5 mg twice daily.
* Titrate by 5 mg to 10 mg per day every week.
* Usual maintenance dose: 10 mg to 20 mg twice daily.
* Maximum dose: 20 mg twice daily (40 mg/day).
*Note: Dosing for pediatric patients should be individualized based on weight and clinical response. Lower doses may be appropriate for patients with certain conditions or those receiving other CNS depressants.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Data is limited, but dose reduction may be necessary.
* **Renal Impairment:** No specific dose adjustment recommendations, but use with caution.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, ataxia, vomiting, fatigue, rash.
* **Serious:** Suicidal ideation/behavior, severe drowsiness, respiratory depression, dependence and withdrawal symptoms, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis).
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is a substrate of CYP3A4. Inhibitors may increase clobazam levels, while inducers may decrease them.
* **Other Anticonvulsants:** Potential for additive CNS depression.
## Monitoring
* Monitor for therapeutic effectiveness (reduction in seizure frequency).
* Monitor for adverse effects, especially somnolence, behavioral changes, ataxia, and signs of respiratory depression.
* Monitor for signs of withdrawal if abruptly discontinued.
* Monitor for suicidal ideation and behavior.
## Clinical Pearls
* Clobazam should be initiated at a low dose and gradually titrated upwards.
* Do not abruptly discontinue clobazam; taper slowly to avoid withdrawal symptoms.
* The risk of serious skin reactions is a significant concern; patients should be educated to seek immediate medical attention if a rash develops.
* Clobazam can be taken with or without food.
* Consider dose reduction in elderly patients or those with hepatic impairment.
***
*This information is intended for clinical decision-making and does not replace the need to consult the official prescribing information and relevant clinical guidelines.* Please verify current prescribing information with the manufacturer's package insert or other reliable sources before making therapeutic decisions.
